Citation: Gandy S, Heppner FL (2005) Breaking Up (Amyloid) Is Hard to Do. PLoS Med 2(12): e417. doi:10.1371/journal.pmed.0020417
Published: December 27, 2005
Copyright: © 2005 Gandy and Heppner. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Competing interests: SG is an advisor to Elan Pharmaceuticals, and receives grant support from the Robert Atkins Foundation. He is Chair of the National Medical and Scientific Advisory Council of the United States Alzheimer's Association. FLH declares that he has no competing interests.
Abbreviations: ADDL, Aβ-derived diffusible ligand; APP, amyloid precursor protein
Standard “Alzheimerology” lore holds that the insolubility of amyloid plaques and neurofibrillary tangles was a great impediment to elucidating the molecular composition of each of these structures. Roughly 77 years passed between Alois Alzheimer's description of the clinical and pathological features of the illness suffered by Auguste D. and the now classical reports from George Glenner, Colin Masters, and Konrad Beyreuther describing partial solubilization, Edman degradation, and primary amino acid sequencing of the Aβ peptide (the protein that accumulates into amyloid plaques) [1–3]. Peter Davies (who discovered the cholinergic deficiency in Alzheimer disease during that same interval ) has long joked that one easy way to purify plaques and tangles is to allow the brain from an affected person to autolyze and liquefy completely (“on a summer sidewalk,” according to one colorful variation), whereupon the macro structure of the organ would disintegrate, leaving behind only fibrous clumps and twists.
There is little wonder, then, that the strategy of treating Alzheimer disease with “plaque busting” drugs was relatively slowly embraced: 20 years passed between the availability of amyloid aggregation assays and the clinical trials of the first specific antiamyloid-aggregation compounds. (“Aggregation” is essentially equivalent to clumping, and amyloid clumping can be monitored in a test tube since floating clumps cause light to disperse in a measurable fashion). Conventional wisdom was nihilistic, holding that therapeutic dissolution of amyloid deposits was probably too slow to be approachable. People love to see a dogma challenged, and the availability of mouse models of Alzheimer disease enabled Brad Hyman's group to show, in 2001, that deposits of human Aβ in the transgenic mouse brain were surprisingly dynamic, forming and, unexpectedly, dissolving over a timescale of days . These data injected new optimism into the pursuit of antiamyloid strategies, and by 2005, over 30 discrete compounds or combinations were in development .
Old Worries Resurface
Now, with publication of a study by David Borchelt's group in this issue of PLoS Medicine , old worries about the efficiency of plaque clearance resurface. David Borchelt, Joanna Jankowsky, and their colleagues report the development of Aβ plaque-forming transgenic mice in which pathology is driven by brain-specific overexpression of a mutated form of the human amyloid precursor protein (APP). The innovation here is that human APP expression due to a genetic trick is extinguishable by adding the antibiotic tetracycline to the mouse food (“tet-off” APP mice). As rightly contended by these authors, the ability to abolish human APP gene expression—instantly and completely—can be conceptually envisioned as equivalent to the most effective antiamyloid strategy imaginable: in other words, a best-case scenario from the point of view of drug efficacy.
The rationale was to see how long human amyloid deposits would persist in a plaque-laden mouse brain once new accretion ceased (i.e., once tetracycline switched off new mutated human APP production). The results are arguably applicable to every antiamyloid strategy delivered to patients impaired by Alzheimer disease, since all are believed to enter therapy with at least some existing brain plaque burden. In this tet-off paradigm, unlike the paradigm used earlier by Hyman and colleagues, amyloid pathology was allowed to accumulate, and then human APP expression was completely shut off. Borchelt and colleagues were unable to detect any change in brain amyloid load for at least six months after complete cessation of Aβ biogenesis. The Borchelt data dovetail well with recent biophysical data, proving that the thermodynamic barrier to redissolution of amyloid fibrils is very high indeed (Figure 1) .
Figure 1. A Large Energy Barrier Prevents Rapid Redissolution of Fibrillar Amyloid
In this issue of PLoS Medicine, Borchelt and colleagues demonstrate in the living amyloid-laden mouse brain that Aβ plaques are cleared very slowly, even if synthesis of new Aβ precursor molecules is extinguished using a tet-off system . In the recent, relevant, but independent, X-ray crystallography study , Nelson et al. envisioned the free-energy plot shown above as a graphic description of the kinetics of transition from monomeric Aβ to fibrillar Aβ (ΔGformation). For the reverse reaction, Nelson et al. envision the ΔGdissolution as the large free-energy barrier to spontaneous solubilization of amyloid fibrils. Presumably, it is this ΔGdissolution that underlies the slow disappearance of brain plaques in the Borchelt study in transgenic mice.
(Illustration: Sapna Khandwala, adapted from )doi:10.1371/journal.pmed.0020417.g001
Implications for Therapy and Prevention
If this mouse model represents the best-case scenario, what are the realistic hopes of success for anti-Aβ therapies in the treatment of human Alzheimer disease? Several points come to mind. First, the recent proposal that oligomeric/dodecameric forms of Aβ (also known as Aβ-derived diffusible ligands [ADDLs]) are the real culprits in mediating Aβ neurotoxicity  provides some hope that ADDLs, not Aβ plaques, represent the most important Aβ biophysical form that must be purged in order to cause a therapeutic benefit. Borchelt and colleagues have not yet determined what happens to ADDL levels in the brains of their tet-off APP mice, but such data are eagerly anticipated.
Second, Borchelt and colleagues' data are consistent with the evidence that all model antiamyloid strategies are superior when initiated long before onset of amyloidosis. Such evidence fuels a new initiative of the United States Alzheimer's Association aimed not at treating but at preventing Alzheimer disease (http://www.alz.org/maintainyourbrain). Interventional strategies early in life should not only prevent amyloid pathology, but also take advantage of the greater regenerative capacity of the human brain at younger ages. The wisdom of preventing Alzheimer disease is further galvanized by the appreciation over the last five years of evidence that many modifiable diet and lifestyle factors (body mass index, cholesterol levels, control of diabetes and blood pressure, and mental and physical exercise) may modulate risk for late-life degenerative dementia .
The Challenges Ahead
Significant challenges lie ahead in understanding how these risks and pathologies are intertwined, but the aging of the baby boom population promises an unprecedented epidemic of dementia if effective interventions are not discovered soon. In the US, the population of individuals age 65 years and over is the fastest growing segment in society, and one-half of individuals over 85 experience dementia . On a practical level, this means that almost everyone will be either a patient or a caregiver in the near future. Disasters such as tsunamis and hurricanes—as painful, dramatic, and expensive as they are—pale in comparison to the cataclysm our aging societies will face if current trends in the epidemiology of this dementing illness continue on unchecked.
This work was supported by United States National Institutes of Health grants NS41017 (to SG) and NS046006 (to FLH).
- 1. Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR (1995) An English translation of Alzheimer's 1907 paper, “Uber eine eigenartige Erkankung der Hirnrinde.”. Clin Anat 8: 429–431.
- 2. Glenner GG, Wong CW (1984) Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120: 885–890.
- 3. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, et al. (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 82: 4245–4249.
- 4. Davies P (1979) Biochemical changes in Alzheimer's disease-senile dementia: Neurotransmitters in senile dementia of the Alzheimer's type. Res Publ Assoc Res Nerv Ment Dis 57: 153–166.
- 5. Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, et al. (2001) Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 7: 369–372.
- 6. Kwon MO, Fischer F, Matthisson M, Herrling P (2004) List of drugs in development for neurodegenerative diseases. Neurodegenerative Dis 1: 113–152.
- 7. Jankowsky JL, Slunt HH, Gonzales V, Savonenko AV, Wen J, et al. (2005) Persistent amyloidosis following suppression of Aβ production in a transgenic model of Alzheimer disease. PLoS Med 2: e355. doi: 10.1371/journal.pmed.0020355.
- 8. Nelson R, Sawaya MR, Balbirnie M, Madsen Aø, Riekel C, et al. (2005) Structure of the cross-beta spine of amyloid-like fibrils. Nature 435: 773–778.
- 9. De Felice FG, Vieira MN, Saraiva LM, Figueroa-Villar JD, Garcia-Abreu J, et al. (2004) Targeting the neurotoxic species in Alzheimer's disease: Inhibitors of Abeta oligomerization. FASEB J 18: 1366–1372.
- 10. Marx J (2005) Neuroscience. Preventing Alzheimer's: A lifelong commitment? Science 309: 864–866.
- 11. Hebert LE, Scherr PA, Beckett LA, Albert MS, Pilgrim DM, et al. (1995) Age-specific incidence of Alzheimer's disease in a community population. JAMA 273: 1354–1359.